Cascadia Healthcare

Cascadia was formed when partners from the skilled nursing and real estate development industry joined forces with a common purpose in mind – to provide a high level of care to patients and families within the region they call home. Our goal is to provide a motivating environment for our employees based on the values of quality work, empowerment and accountability. Cascadia is driven by honest hard work and we believe that strong partnerships and quality care are the outcome.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

news image

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

CELL AND GENE THERAPY

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

news image

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More

CELL AND GENE THERAPY

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

news image

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More
news image

INDUSTRIAL IMPACT

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

news image

CELL AND GENE THERAPY

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More
news image

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

CELL AND GENE THERAPY

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us